These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33388856)

  • 1. Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies.
    Gordillo CA; Parmar S; Blanco M; Delille EM; Assal A; Mapara M; Reshef R
    Ann Hematol; 2021 Jul; 100(7):1863-1870. PubMed ID: 33388856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report.
    Okada K; Yamasaki K; Nitani C; Fujisaki H; Osugi Y; Hara J
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27953. PubMed ID: 31393093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
    Malek E; Gupta V; Creger R; Caimi P; Vatsayan A; Covut F; Bashir Q; Champlin R; Delgado R; Rondon G; Cooper B; de Lima M; Lazarus HM; Qazilbash M
    Leuk Lymphoma; 2018 Aug; 59(8):1905-1912. PubMed ID: 29295650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
    Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Y
    Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
    Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
    Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
    Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
    Miyamoto T; Yoshimoto G; Kamimura T; Muta T; Takashima S; Ito Y; Shiratsuchi M; Choi I; Kato K; Takenaka K; Iwasaki H; Takamatsu Y; Teshima T; Akashi K
    Int J Hematol; 2013 Sep; 98(3):337-45. PubMed ID: 23877150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
    Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
    Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.
    Lee SY; Meehan RS; Seldin DC; Sloan JM; Quillen K; Shelton A; Brauneis D; Sanchorawala V
    Bone Marrow Transplant; 2016 Oct; 51(10):1318-1322. PubMed ID: 27183092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
    Mark TM; Reid W; Niesvizky R; Gergis U; Pearse R; Mayer S; Greenberg J; Coleman M; Van Besien K; Shore T
    Biol Blood Marrow Transplant; 2013 May; 19(5):831-7. PubMed ID: 23454184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
    Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions.
    Tendas A; Marchesi F; Mengarelli A; Annibali O; Tomarchio V; Saltarelli D; Chierichini A; Di Venanzio M; Sollazzo F; Piedimonte M; Cupelli L; Bruno A; De Angelis G; Delbono L; Niscola P; Perrotti AP; de Fabritiis P; Arcese W;
    Support Care Cancer; 2019 Mar; 27(3):793-803. PubMed ID: 30564934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.